Health & Medical · Week of Nov 9, 2026
PAVmed, Photocure, IceCure report on Medicare, approvals: health week
PAVmed, Photocure, IceCure, Dyania Health and others report on Medicare reimbursement, regulatory steps, patents, AI deployment and awareness campaigns.
Medicare reimbursement for diagnostic tests was the clearest shared thread among this week's health releases. PAVmed says its subsidiary Lucid Diagnostics began receiving Medicare payments for the EsoGuard test in October after submitting claims to Novitas. Photocure, by contrast, says its AssureMDx bladder cancer test was left out of a Novitas coverage determination dated November 6, 2026, though it expects a CMS pricing decision before year-end and initial revenue in 2027.
Elsewhere, device and technology companies reported regulatory and commercial steps. IceCure Medical added a Chinese patent following its September market approval there, and Dyania Health described a collaboration with NVIDIA to run clinical reasoning AI inside hospital infrastructure. The Global Wellness Institute put the global wellness economy at $7.5 trillion in 2025, Breakthrough T1D expanded its awareness campaign for World Diabetes Day, Aflac raised its dividend and CeraVe announced a film marketing tie-in.






Breakthrough T1D, Formerly JDRF
Breakthrough T1D Honors World Diabetes Day with Expanded Global "See T1D" Campaign, Spotlighting Life with Type 1 Diabetes

This roundup is written with AI assistance from the press releases listed above, using only what they state. The releases are the companies' own announcements, not Times Beats reporting.